Talk:Nomenclature of monoclonal antibodies

Could somebody fix the table, please? The borders are not correct. NCurse _work 14:26, 9 July 2006 (UTC)

:Hmm. I tried several different things and wasn't able to fix it. I'll try asking at the Village Pump. — Knowledge Seeker দ 07:54, 10 July 2006 (UTC)

:OK, never mind, I used a quite inelegant solution. — Knowledge Seeker দ 08:19, 10 July 2006 (UTC)

Merger of -mab stems: -amab, -emab, -imab, -omab, -umab, -ximab, -zumab, and -axomab was proposed by BlakeCS on 30 December 2006. I agree that this information could be placed in a single table in this, the Nomenclature of monoclonal antibodies article. --Bejnar 19:21, 30 December 2006 (UTC)

• Now that we have the table, is there anything to do but redirect them? Night Gyr (talk/Oy) 03:09, 31 December 2006 (UTC)

::No, I think redirection is in order at this point. — Swpb ^{talk contribs} 06:19, 31 December 2006 (UTC)

:::Done. — Swpb ^{talk contribs} 08:08, 1 January 2007 (UTC)

Stems what I've made up is: murine hybrids: -exomab, -ixomab, -oxomab, and -uxomab. Two-letter combinations for targets: -o(s). Three-letter combinations for targets: -mu(l)- (muscular). Four-letter combinations for targets: -neu(r)- (nervous system), -tox(a)- (toxin), -fu(ng)- (fungal). -xomab means a murine hybrid. BlakeCS 05:45, 21 January 2007 (UTC)

I think this page might be more accessible to beginners if several more examples were given and analyzed. This nomenclature is unique, and it takes a while to get your mind around it.

A linguist might say that these words are agglutinative, with a string of components but no definite stem (if -mab is viewed as a stem, then words might be called synthetic). Whole languages can be agglutinative, like spoken French or like the Algonkian languages of North America, or synthetic like Latin, Sanskrit, or Turkish.

Either way, they don't work like English, and the learner needs all the help he can get.

Or maybe this elderly physician just needs to retire!

Bob Richmond (talk) 00:35, 1 November 2008 (UTC)Bob Richmond

• Expand on targets: no information whether the mab is therapeutic, prophylactic or diagnostic
• {{done}} --ἀνυπόδητος (talk) 18:52, 8 June 2010 (UTC)
• Short linguistic discussion on infix/suffix/stem confusion
• {{done}} in International Nonproprietary Name --ἀνυπόδητος (talk) 13:26, 28 November 2010 (UTC)
• Include history section [http://www.who.int/medicines/services/inn/generalpoliciesmonoclonalantibodiesjan10.pdf] [http://www.ama-assn.org/ama/pub/about-ama/our-people/coalitions-consortiums/united-states-adopted-names-council/naming-guidelines/naming-biologics/monoclonal-antibodies.shtml]
• {{done}} --ἀνυπόδητος (talk) 14:51, 8 December 2010 (UTC)
• Explain affixes "under discussion": -n(e)-, -xizu-

--ἀνυπόδητος (talk) 16:27, 8 June 2010 (UTC)

{{Talk:Nomenclature of monoclonal antibodies/GA1}}

Could I just point out that this article is not about the nomenclature of monoclonal antibodies? It is about the nomenclature of *therapeutic* monoclonal antibodies. A monoclonal antibody can be called anything you like. It is only when a monoclonal antibody which is intended to become a drug reaches the stage of development where an INN is required that the system so tortuously described in the article kicks in.

The [https://www.ama-assn.org/about/united-states-adopted-names/monoclonal-antibodies USAN 2019 Naming Policy] states that "[t]he target infix places information about the action or use of the antibody in the name", which is in conflict with the currently unsourced text in the article. I have yet to find any information from WHO literature. I will remove those paragraph if there are no evidence otherwise. -Mys_721tx (talk) 18:28, 6 December 2020 (UTC)

"These are officially called substems and sometimes erroneously infixes, even by the USAN Council itself." is an assertion not existing in the source and should be removed. -Mys_721tx (talk) 19:02, 6 December 2020 (UTC)